Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
19.9M
-
Shares change
-
-517K
-
Total reported value, excl. options
-
$78.1M
-
Value change
-
-$2.1M
-
Put/Call ratio
-
0.04
-
Number of buys
-
21
-
Number of sells
-
-32
-
Price
-
$3.93
Significant Holders of Skye Bioscience, Inc. - Common Stock, par value $0.001 per share (SKYE) as of Q3 2025
80 filings reported holding SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
Skye Bioscience, Inc. - Common Stock, par value $0.001 per share (SKYE) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.9M shares
of 31M outstanding shares and own 64.14% of the company stock.
Largest 10 shareholders include 5AM Venture Management, LLC (9.68M shares), Versant Venture Management, LLC (2.01M shares), BAKER BROS. ADVISORS LP (1.45M shares), Schonfeld Strategic Advisors LLC (1.19M shares), VANGUARD GROUP INC (883K shares), Ensign Peak Advisors, Inc (767K shares), Driehaus Capital Management LLC (620K shares), SPHERA FUNDS MANAGEMENT LTD. (479K shares), Alyeska Investment Group, L.P. (456K shares), and MILLENNIUM MANAGEMENT LLC (402K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.